OTC antifungal testing
Executive Summary
FDA tells W. F. Young in Nov. 4 letter that T. rubrum fungal isolate must be prevalent for a clinical study of tinea pedis. "With regard to fungal isolates," FDA said, "at a minimum, a significant number of clinical cases need to be positive for T. rubrum because T. rubrum is considered one of the most common orgamisms found in tinea pedis and one of the most difficult to eradicate".
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.